/IDXX
IDEXX Laboratories, Inc.
IDXX • NASDAQIDXX • NASDAQ • Healthcare
$648.70+2.07%+13.16
$648.70+2.07%(+13.16)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
92Bullish
Risk
52Moderate
Momentum
49Neutral
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
61.8%▲0.8pp
Revenue after COGS
Operating
31.6%▲2.7pp
After operating expenses
Net
24.6%▲1.8pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
51.1
Price vs earnings
EV/EBITDA
37.5
Enterprise value
FCF Yield
1.9%
Cash generation
Earnings Yield
2.0%
Inverse of P/E
Capital Efficiency
46
GoAI Quality ScoreExcellent
ROEReturn on Equity
66.0%Strong
ROAReturn on Assets
31.6%Strong
ROICReturn on Invested Capital
40.3%Strong
Financial Health
Current RatioAdequate
1.17
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.61x
Debt repayment capacity (<3x)
Income QualityStrong
1.11
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B |
| Gross Profit | $2.66B | $2.38B | $2.19B | $2.00B | $1.89B |
| Gross Margin | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% |
| Operating Income | $1.36B | $1.13B | $1.10B | $898.76M | $932.03M |
| Net Income | $1.06B | $887.87M | $845.04M | $679.09M | $744.85M |
| Net Margin | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% |
| EPS | $13.17 | $10.77 | $10.17 | $8.12 | $8.74 |
Average Price Target
$784.38▲ 20.9% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for IDEXX Laboratories, Inc., the average price target is $784.38, with a high forecast of $830.00 and a low forecast of $730.00. The average price target represents a 20.9% increase from the current price of $648.70.
Highest
$830.00
Average
$784.38
Lowest
$730.00
Rating Distribution
Strong Buy
0
0%
Buy
13
59%
Hold
8
36%
Sell
1
5%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Piper Sandler● Maintain
Neutral
2026-02-09Barclays● Maintain
Overweight
2026-02-05BTIG● Maintain
Buy
2026-02-03UBS● Maintain
Neutral
2026-02-03BTIG● Maintain
Buy
2025-11-04Morgan Stanley● Maintain
Overweight
2025-11-04UBS● Maintain
Neutral
2025-11-04JP Morgan● Maintain
Overweight
2025-11-04Stifel▲ Upgrade
Hold→Buy
2025-10-31Morgan Stanley● Maintain
Overweight
2025-08-15Earnings History & Surprises
BEAT RATE
94%
Last 18 quarters
AVG SURPRISE
+6.1%
EPS vs Estimate
BEATS / MISSES
17/0
1 met exactly
LATEST EPS
$3.08
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+5.1%
$3.08 vs $2.93
Q4 '25
+8.3%
$3.40 vs $3.14
Q3 '25
+10.7%
$3.63 vs $3.28
Q2 '25
+3.9%
$2.96 vs $2.85
Q1 '25
+9.6%
$2.62 vs $2.39
Q4 '24
+4.5%
$2.80 vs $2.68
Q3 '24
+4.9%
$3.02 vs $2.88
Q2 '24
+5.2%
$2.81 vs $2.67
Q1 '24
+9.4%
$2.32 vs $2.12
Q4 '23
+6.8%
$2.53 vs $2.37
Q3 '23
+8.1%
$2.67 vs $2.47
Q2 '23
+5.4%
$2.55 vs $2.42
No investor questions available.
Latest News
No news available